Action Duchenne
Mehreen Arif has a diverse work experience spanning multiple roles and organizations. Mehreen is currently working as the Chief Scientific Officer at Action Duchenne since March 2022. Prior to this, they were a Postdoctoral Research Scientist at GSK and a Postdoctoral Scientist at King's College London, both starting in February 2018. Mehreen also gained experience as a PhD Researcher at the University of Surrey from October 2014 to April 2018. Their earlier experience includes working as a Student Ambassador at the University of Surrey from October 2013 to July 2014, and as a Research and Development Technician at BTG from September 2012 to September 2013.
Mehreen Arif completed their education in a field related to oncology and biomedical sciences. Mehreen obtained their Doctor of Philosophy (PhD) degree in Oncology- Oncolytic Virus Immunotherapy from the University of Surrey, where they studied from 2014 to 2017. Prior to that, they completed their Bachelor of Science (BSc) in Biomedical Sciences at the same university from 2010 to 2014. Their earlier education includes completing A levels at Lahore Grammar School from 2008 to 2010, where they studied Biology, Physics, Chemistry, and Food Sciences.
This person is not in any teams
This person is not in any offices
Action Duchenne
Duchenne muscular dystrophy (DMD) is a rare and complex genetic muscle wasting condition, mainly affecting males. It is one of the most severe muscular dystrophies, with muscle weakness appearing in early childhood between the ages of 2 and 5. Our vision is clear; a world where lives are no longer limited by Duchenne muscular dystrophy. We achieve this vision through our vital work; * Funding research for everyone living with Duchenne * World-class support for families * Cutting-edge science education programmes